EHA 2016

 
 
 

Bella Center in Copenhagen, Denmark, site of the 21st Congress of the European Hematology Association, which took place June 9-12, 2016.

 

Drug enables transfusion independence in lower-risk MDS

Jen Smith Read Article
Published: 06/24/16

platzbecker-uwe-240.jpg
Uwe Platzbecker, MD

Results from a pair of phase 2 trials suggest luspatercept can produce erythroid responses and enable transfusion independence in patients with lower-risk myelodysplastic syndromes (MDS). In a 3-month base study, 51% of patients treated with luspatercept had an erythroid response, and 35% achieved transfusion independence. In an ongoing extension study, 81% of luspatercept-treated patients have had an . . . [Read Article]

Stopping TKI therapy can be safe, study suggests

Jen Smith Read Article
Published: 06/23/16

richter-johan-240.jpg
Johan Richter, MD, PhD

Results of a large study suggest that stopping treatment with tyrosine kinase inhibitors (TKIs) can be safe for patients with chronic myeloid leukemia (CML) in deep molecular response (MR4). Six months after patients stopped receiving a TKI, the relapse-free survival was 62%. At 12 months, it was 56%. Having a longer duration of TKI treatment and a longer duration of deep molecular response were both associated with a higher likelihood of relapse-free survival. [Read Article]

Site of major bleeding differs with NOACs and VKAs

Jen Smith Read Article
Published: 06/21/16

franco-laura-eha2016-240.jpg
Laura Franco, MD

Results of a new study suggest that vitamin K antagonists (VKAs) and non-VKA oral anticoagulants (NOACs) can both confer an increased risk of major bleeding, but the type of bleeding tends to differ with the type of anticoagulant. The research showed that patients taking VKAs were more likely to be hospitalized for intracranial hemorrhage (ICH), while patients taking NOACs were more likely to be hospitalized for gastrointestinal (GI) bleeding. [Read Article]

Platelet transfusion deemed ‘harmful’ in patient group

Jen Smith Read Article
Published: 06/20/16

eha2016-crowd-aerial-220.jpg
Attendees at the 21st
Congress of the European
Hematology Association

Results of the phase 3 PATCH trial suggest that platelet transfusions are not beneficial and can actually cause harm in patients with intracerebral hemorrhage (ICH) associated with antiplatelet therapy. The study showed that the odds of death or dependence at 3 months were significantly higher among patients who received a platelet transfusion plus standard care than among patients who received standard care alone. [Read Article]

Drug can address unmet need in cHL, doc says

Jen Smith Read Article
Published: 06/18/16

younes-anas-eha2106-240.jpg
Anas Younes, MD

The PD-1 checkpoint inhibitor nivolumab can address an unmet need in patients with classical Hodgkin lymphoma (cHL) who have progressive or relapsed disease, according to a speaker at the 21st Congress of the European Hematology Association. In the phase 2 Checkmate-205 trial, nivolumab produced an objective response rate of 66% in cHL patients who had relapsed or progressed after autologous . . . [Read Article]

Immunotherapy ‘outcompetes’ chemo in rel/ref B-ALL

Jen Smith Read Article
Published: 06/16/16

topp-max-240.jpg
Max S. Topp, MD

Interim results from the phase 3 TOWER trial suggest blinatumomab can prolong overall survival (OS) when compared to standard care in adults with Ph-negative, relapsed/refractory B-cell precursor acute lymphoblastic leukemia (B-ALL). The median OS for patients treated with blinatumomab was nearly double the median OS of patients who received standard chemotherapy (investigator’s choice of 4 different regimens). [Read Article]

ESA benefits lower-risk MDS patients

Jen Smith Read Article
Published: 06/16/16

platzbecker-uwe-240.jpg
Uwe Platzbecker, MD

The erythropoiesis-stimulating agent (ESA) darbepoetin alfa can provide a clinical benefit in patients with lower-risk myelodysplastic syndromes (MDS), a phase 3 trial suggests. In the ARCADE trial, darbepoetin alfa significantly reduced the incidence of red blood cell (RBC) transfusions in patients with low- and intermediate-1 risk myelodysplastic syndrome (MDS), when compared to placebo. The ESA also significantly improved erythroid response. [Read Article]

A new standard of care for relapsed/refractory MM?

Jen Smith Read Article
Published: 06/15/16

dimopolous-240.jpg
Meletios A. Dimopoulos, MD

The combination of daratumumab, lenalidomide, and dexamethasone (DRd) could become a new standard of care for patients with relapsed or refractory multiple myeloma (MM), according to a speaker at the 21st Congress of the European Hematology Association. In the phase 3 POLLUX study, DRd conferred the highest response rate reported to date in the treatment of relapsed/refractory MM. [Read Article]

Inotuzumab bests standard of care in adult ALL

HT Staff Read Article
Published: 06/13/16

Kantarjian_Hagop_MD_Credit_MD_Anderson_230.jpg
Hagop M. Kantarjian, MD
Photo courtesy of MDACC

In multiple categories, the antibody-drug conjuagate inotuzumab ozogamicin achieved significantly better results than the standard of care in the treatment of adults with acute lymphoblastic leukemia (ALL). Patients in the inotuzumab arm experienced a higher rate of complete remissions, a greater frequency of achieving minimal residual disease negativity, and longer progression-free survival and overall survival. [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}